Publicaciones en colaboración con investigadores/as de Yale University (16)

2023

  1. CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary

    Cancer discovery, Vol. 13, Núm. 3, pp. 552-569

  2. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

    Gynecologic Oncology, Vol. 178, pp. 119-129

2021

  1. A burned-out cd8+ t-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy

    Cancer Discovery, Vol. 11, Núm. 7, pp. 1700-1715

  2. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma

    European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091

2020

  1. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

    Nature Medicine, Vol. 26, Núm. 5, pp. 688-692

  2. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4663-4673

  2. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Cell, Vol. 176, Núm. 1-2, pp. 334-347.e12

  3. Immunotherapy in non-small cell lung cancer: Facts and hopes

    Clinical Cancer Research, Vol. 25, Núm. 15, pp. 4592-4602

  4. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus

    Science Translational Medicine, Vol. 11, Núm. 522

2018

  1. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

    Nature Communications, Vol. 9, Núm. 1

2017

  1. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 389, Núm. 10064, pp. 67-76

  2. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study

    Annals of Oncology, Vol. 28, Núm. 12, pp. 3044-3050

  3. Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours

    Journal of Translational Medicine, Vol. 15, Núm. 1

2016

  1. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 387, Núm. 10031, pp. 1909-1920

2014

  1. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation

    Cancer Journal (United States), Vol. 20, Núm. 4, pp. 256-261